Graphene Far-Infrared Reduced Anxiety by 65% and Improved Cognition by 83% in Older Adults
In 2024, a team of researchers from Ningbo University Affiliated Kangning Hospital, the Chinese Academy of Sciences Institute of Psychology, and Xiamen University — including Academician Zheng Nanfeng — published a randomized controlled trial in BMC Geriatrics. They wanted to know whether a simple, non-invasive graphene far-infrared intervention could measurably improve mental health in older adults.
The study enrolled 108 older adults and divided them into groups. One group received daily 30-minute sessions of graphene far-infrared exposure at 40°C for four weeks. The graphene FIR group showed a 65% reduction in anxiety scores as measured by the GAD-7 scale, and an 83% improvement in cognitive function as measured by the s-MoCA assessment — both statistically significant compared to the control group.
What makes this finding notable is the mechanism: unlike pharmaceutical interventions, the graphene FIR approach is non-invasive and non-pharmacological. The researchers observed that far-infrared photons at the 9.4-micrometer wavelength — precisely where water molecules in tissue absorb energy most efficiently — appeared to support the body's intrinsic cellular processes, including microcirculation and mitochondrial energy production.
This study is particularly significant because it comes from a rigorous RCT design, published in a peer-reviewed SCI-indexed journal, and includes Academician Zheng Nanfeng — one of China's most respected materials scientists and a key figure in graphene research — as a co-author. Zheng's involvement links the study directly to the IKKEM (Jiageng Innovation Laboratory) ecosystem, the same institution that incubates XIHE Technology.
XIHE Interpretation
Why This Study Matters for XIHE Technology
This RCT validates a core premise of XIHE's technology platform: that precision-calibrated graphene far-infrared at 9.4μm produces measurable, statistically significant biological outcomes — not through heat, but through photon-tissue interaction at the cellular level.
The fact that the intervention required only 30 minutes of daily exposure at a moderate 40°C aligns with XIHE's product design philosophy: gentle, sustained resonance rather than intense thermal stress. The XIHE CAPSULE and CABIN are engineered to deliver this exact experience — consistent, precision-controlled far-infrared exposure over programmable sessions.
What B2B Partners Should Know
- Published, peer-reviewed evidence. This is not a white paper or internal report. It is an SCI-indexed RCT in a respected journal. Partners can cite it in their own regulatory submissions and marketing materials.
- Academician Zheng Nanfeng is a co-author. His presence on the author list signals institutional credibility at the highest level — he is a CAS Academician and co-founder of IKKEM, XIHE's joint-equity parent institution.
- Mental health and cognitive aging are massive addressable markets. The global population over 60 will reach 2.1 billion by 2050. Anxiety and cognitive decline are among the most pressing health concerns in this demographic. This study provides evidence that graphene FIR may play a supportive role — not as a treatment, but as a wellness intervention that supports the body's intrinsic regulatory systems.
- Non-pharmacological advantage. In an era of growing concern about polypharmacy in older adults, a non-invasive, non-drug intervention that shows measurable mental health benefits has strong appeal for senior living facilities, longevity clinics, and healthcare systems.
XIHE's Position
XIHE does not manufacture clinical research. We manufacture precision graphene far-infrared technology. Independent researchers, including those at Ningbo University and the CAS Institute of Psychology, choose to use our materials because of their spectral precision and consistency. When their published findings align with the biophysical mechanisms we engineer for, it validates our approach at the most credible level: third-party, peer-reviewed science.
Compliance Note
This page describes published third-party research. XIHE Technology does not claim that its products treat, cure, or prevent anxiety, depression, dementia, or any medical condition. The study investigated graphene far-infrared as a general wellness intervention; the outcomes reported are from the published literature and are not XIHE marketing claims. XIHE's role was as a material/technology provider to the research team.